Compare GBX & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | ODTX |
|---|---|---|
| Founded | 1974 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1996 | 2025 |
| Metric | GBX | ODTX |
|---|---|---|
| Price | $40.19 | $20.55 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $45.33 | $35.75 |
| AVG Volume (30 Days) | ★ 307.7K | 245.6K |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 28.02 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $3,240,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.54 | N/A |
| P/E Ratio | $18.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.23 | $15.10 |
| 52 Week High | $59.19 | $29.05 |
| Indicator | GBX | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.04 | 48.10 |
| Support Level | N/A | $22.30 |
| Resistance Level | $43.90 | $28.53 |
| Average True Range (ATR) | 0.96 | 1.99 |
| MACD | -0.13 | -0.22 |
| Stochastic Oscillator | 1.83 | 50.43 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.